— Know what they know.
Not Investment Advice

TRVI NASDAQ

Trevi Therapeutics, Inc.
1W: -6.1% 1M: -4.3% 3M: +33.1% YTD: +19.1% 1Y: +118.9% 3Y: +451.0% 5Y: +587.4%
$14.13
-0.03 (-0.21%)
 
Weekly Expected Move ±6.3%
$12 $13 $14 $15 $16
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 45 · $2.0B mcap · 118M float · 1.29% daily turnover · Short 64% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
33.5 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: 977.9%
Cost Advantage
33
Intangibles
25
Switching Cost
38
Network Effect
47
Scale
27
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. TRVI has No discernible competitive edge (33.5/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. ROIC of 977.9% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$20
Low
$25
Avg Target
$30
High
Based on 2 analysts since May 5, 2026 earnings
Analyst Recommendations
Strong Buy: 1Buy: 16Hold: 0Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$25.00
Analysts2
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-08 Stifel Nicolaus Annabel Samimy $18 $30 +12 +113.5% $14.05
2026-05-06 Morgan Stanley $19 $20 +1 +36.4% $14.66
2025-12-19 Stifel Nicolaus Initiated $18 +47.7% $12.19
2025-11-19 Leerink Partners Roanna Ruiz Initiated $16 +41.5% $11.31
2025-11-14 Morgan Stanley Judah Frommer Initiated $19 +62.7% $11.68
2025-11-14 Oppenheimer Leland Gershall $12 $24 +12 +103.4% $11.80
2024-10-22 H.C. Wainwright Oren Livnat Initiated $6 +79.1% $3.35
2024-10-04 B.Riley Financial Mayank Mamtani Initiated $6 +98.7% $3.02
2022-07-09 Oppenheimer Leland Gershall Initiated $12 +203.8% $3.95

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
May 22, 2026
DCF
2
ROE
1
ROA
1
D/E
4
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. TRVI receives an overall rating of C. Strongest factors: D/E (4/5). Areas of concern: DCF (2/5), ROE (1/5), ROA (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-05-06 C- C
2026-04-01 C C-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

Grade A+
Profitability
Balance Sheet
85
Earnings Quality
70
Growth
Value
28
Momentum
Safety
100
Cash Flow

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
100.16
Safe Zone
Piotroski F-Score
4/9
Beneish M-Score
Ohlson O-Score
-1.14
Bankruptcy prob: 24.2%
Moderate
Credit Rating
A+
Score: 75.6/100
Trend: Improving
Earnings Quality
OCF/NI: 0.99x
Accruals: -0.2%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. TRVI scores 100.16, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. TRVI scores 4/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. TRVI's implied 24.2% bankruptcy probability is elevated and warrants attention to the balance sheet. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. TRVI receives an estimated rating of A+ (score: 75.6/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-45.10x
PEG
-1.27x
P/S
0.00x
P/B
11.95x
P/FCF
-54.38x
P/OCF
EV/EBITDA
-32.77x
EV/Revenue
EV/EBIT
-32.70x
EV/FCF
-48.51x
Earnings Yield
-2.63%
FCF Yield
-1.84%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. TRVI currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.998
NI / EBT
×
Interest Burden
0.964
EBT / EBIT
×
EBIT Margin
EBIT / Rev
×
Asset Turnover
0.000
Rev / Assets
×
Equity Multiplier
1.076
Assets / Equity
=
ROE
-32.2%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. TRVI's ROE of -32.2% is driven by A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1772 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$14.13
Median 1Y
$9.89
5th Pctile
$2.06
95th Pctile
$47.62
Ann. Volatility
93.9%
Analyst Target
$25.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Jennifer Good
President and Chief Executive Officer
$622,382 $— $3,944,892
James Cassella, Ph.D.
Chief Development Officer
$488,270 $— $1,637,220
Farrell Simon, Pharm.
D. Chief Commercial Officer
$370,067 $— $1,355,897

CEO Pay Ratio

8:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $3,944,892
Avg Employee Cost (SGA/emp): $466,176
Employees: 34

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
34
+30.8% YoY
Revenue / Employee
Profit / Employee
$-1,257,618
NI: $-42,759,000
SGA / Employee
$466,176
Avg labor cost proxy
R&D / Employee
$984,647
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -85.7% -85.4% -1.5% -1.5% -1.4% -1.5% -46.8% -45.3% -43.9% -43.0% -30.6% -35.3% -40.8% -46.6% -52.6% -52.0% -51.9% -50.3% -30.2% -32.2% -32.25%
ROA -65.5% -65.2% -79.3% -76.9% -72.8% -75.2% -36.1% -35.0% -33.8% -33.1% -27.4% -31.6% -36.5% -41.7% -47.8% -47.3% -47.2% -45.8% -28.1% -30.0% -29.97%
ROIC 7.6% 7.5% 5.0% 4.8% 4.6% 4.9% 6.1% 6.2% 6.3% 6.5% -29.3% -33.1% -37.3% -41.7% 5.9% 5.8% 5.9% 5.8% 9.1% 9.8% 9.78%
ROCE -81.9% -81.2% -1.3% -1.2% -1.2% -1.2% -25.6% -24.8% -24.1% -23.9% -34.3% -40.0% -46.4% -53.1% -47.8% -47.2% -47.2% -45.7% -23.3% -25.8% -25.80%
Gross Margin
Operating Margin
Net Margin
EBITDA Margin
FCF Margin
OCF Margin
ROE 3Y Avg snapshot only -37.69%
ROE 5Y Avg snapshot only -66.40%
ROA 3Y Avg snapshot only -34.61%
ROIC Economic snapshot only -22.66%
Cash ROA snapshot only -23.42%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -1.29 -0.87 -0.50 -2.06 -5.37 -3.30 -6.50 -6.46 -8.64 -8.09 -4.59 -10.23 -7.77 -7.62 -9.12 -15.62 -15.07 -28.95 -42.60 -38.08 -45.104
P/S Ratio 0.000
P/B Ratio 1.66 1.11 0.99 3.97 9.80 6.21 1.76 1.70 2.20 2.01 1.61 4.16 3.65 4.09 4.38 7.42 7.16 13.32 9.94 9.48 11.952
P/FCF -1.44 -0.96 -0.58 -2.38 -6.26 -3.77 -6.68 -6.18 -7.10 -6.78 -4.19 -10.08 -9.16 -9.61 -11.41 -17.91 -16.70 -30.16 -63.64 -54.38 -54.384
P/OCF
EV/EBITDA -0.43 0.02 0.16 -1.44 -4.85 -2.71 -2.79 -2.62 -4.73 -4.04 -1.81 -7.86 -5.68 -5.79 -6.91 -13.41 -12.85 -26.70 -38.29 -32.77 -32.774
EV/Revenue
EV/EBIT -0.43 0.02 0.16 -1.44 -4.84 -2.71 -2.79 -2.62 -4.71 -4.02 -1.80 -7.83 -5.66 -5.77 -6.89 -13.36 -12.81 -26.61 -38.16 -32.70 -32.700
EV/FCF -0.46 0.02 0.18 -1.60 -5.43 -2.98 -2.76 -2.41 -3.75 -3.30 -1.62 -7.68 -6.68 -7.29 -8.62 -15.33 -14.21 -27.74 -57.09 -48.51 -48.513
Earnings Yield -77.4% -1.2% -2.0% -48.5% -18.6% -30.3% -15.4% -15.5% -11.6% -12.4% -21.8% -9.8% -12.9% -13.1% -11.0% -6.4% -6.6% -3.5% -2.3% -2.6% -2.63%
FCF Yield -69.3% -1.0% -1.7% -42.0% -16.0% -26.5% -15.0% -16.2% -14.1% -14.7% -23.9% -9.9% -10.9% -10.4% -8.8% -5.6% -6.0% -3.3% -1.6% -1.8% -1.84%
Price/Tangible Book snapshot only 9.479
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 8.33 8.33 2.98 2.98 2.98 2.98 9.15 9.15 9.15 9.15 15.03 15.03 15.03 15.03 10.41 10.41 10.41 10.41 19.66 19.66 19.659
Quick Ratio 8.33 8.33 2.98 2.98 2.98 2.98 9.15 9.15 9.15 9.15 15.03 15.03 15.03 15.03 10.41 10.41 10.41 10.41 19.66 19.66 19.659
Debt/Equity 0.52 0.52 0.86 0.86 0.86 0.86 0.09 0.09 0.09 0.09 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.00 0.00 0.004
Net Debt/Equity -1.13 -1.13 -1.30 -1.30 -1.30 -1.30 -1.04 -1.04 -1.04 -1.04 -0.99 -0.99 -0.99 -0.99 -1.07 -1.07 -1.07 -1.07 -1.02 -1.02 -1.023
Debt/Assets 0.30 0.30 0.38 0.38 0.38 0.38 0.07 0.07 0.07 0.07 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.004
Debt/EBITDA -0.42 -0.42 -0.45 -0.46 -0.49 -0.47 -0.33 -0.34 -0.35 -0.35 -0.05 -0.04 -0.03 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.016
Net Debt/EBITDA 0.91 0.91 0.68 0.70 0.74 0.72 3.98 4.11 4.22 4.27 2.86 2.45 2.11 1.85 2.23 2.26 2.26 2.33 4.39 3.97 3.966
Interest Coverage -32.53 -28.09 -27.25 -26.20 -24.78 -25.87 -24.10 -24.88 -27.88 -39.69 -73.79 -210.30 -4308.33 -6334.14 -11984.50 -15793.33 -23671.50 -45888.00
Equity Multiplier 1.73 1.73 2.25 2.25 2.25 2.25 1.14 1.14 1.14 1.14 1.08 1.08 1.08 1.08 1.11 1.11 1.11 1.11 1.06 1.06 1.056
Cash Ratio snapshot only 19.311
Cash to Debt snapshot only 250.013
FCF to Debt snapshot only -42.414
Defensive Interval snapshot only 1309.0 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Inventory Turnover
Receivables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Payables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.05 0.05 0.04 0.03 0.01 0.01 0.00 0.01 0.009
DSO
DIO 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 73989 73989 73989 73989 24330 12165 7885 7885 8587 12542 25084 25084 39318 39318.0 days
Cash Conversion Cycle
Fixed Asset Turnover snapshot only 0.000
Cash Velocity snapshot only 0.000
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue
Net Income -17.8% -17.4% -3.6% -0.7% 11.2% 7.9% 14.1% 14.2% 12.3% 16.8% 0.3% -18.9% -41.9% -65.7% -64.8% -41.1% -22.0% -3.5% 10.8% 3.7% 3.67%
EPS -4.4% 1.5% 11.1% 36.5% 70.0% 71.1% 81.1% 73.2% 47.1% 42.3% 1.7% -17.8% -38.6% -62.9% -54.7% -19.4% 5.4% 27.9% 35.0% 22.2% 22.18%
FCF -16.0% -20.3% 0.3% 10.9% 14.8% 11.2% 2.1% -3.6% -24.3% -13.5% -12.4% -15.5% 1.1% -10.0% -20.2% -21.3% -29.9% -25.4% 25.2% 22.7% 22.67%
EBITDA -14.2% -13.7% -1.4% 0.7% 12.0% 8.1% 14.5% 14.3% 11.9% 15.8% -2.1% -22.8% -46.6% -69.6% -67.2% -41.8% -22.2% -3.5% 10.7% -0.1% -0.10%
Op. Income -10.6% -11.1% 0.0% 1.7% 10.8% 5.6% 7.9% 3.1% -3.1% -0.4% -13.4% -25.7% -39.2% -52.4% -51.9% -33.5% -19.3% -6.5% 4.3% -3.3% -3.29%
OCF Growth snapshot only -9.78%
Asset Growth snapshot only 74.43%
Equity Growth snapshot only 83.90%
Debt Growth snapshot only -27.03%
Shares Change snapshot only 23.79%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y
Revenue 5Y
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y
Gross Profit 5Y
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 23.4% 23.4% 27.0% 27.0% 27.0% 27.0% 23.8% 23.8% 23.8% 23.8% 42.3% 42.3% 42.3% 42.3% 16.3% 16.3% 16.29%
Assets 5Y 34.3% 34.3% 13.1% 13.1% 13.1% 13.1% 32.6% 32.6% 32.63%
Equity 3Y -0.4% -0.4% 25.4% 25.4% 25.4% 25.4% 44.6% 44.6% 44.6% 44.6% 80.0% 80.0% 80.0% 80.0% 19.5% 19.5% 19.47%
Book Value 3Y -33.4% -36.6% -29.0% -29.1% -29.1% -28.9% -17.4% -16.1% -15.5% -13.5% 6.0% 15.2% 38.7% 40.5% 4.8% 4.9% 4.92%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earnings Stability 0.89 0.93 0.82 0.81 0.63 0.67 0.32 0.06 0.36 0.28 0.15 0.05 0.50 0.56 0.51 0.46 0.48 0.50 0.41 0.60 0.603
Margin Stability
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.500
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.93 0.93 0.99 1.00 0.96 0.97 0.94 0.94 0.95 0.93 1.00 0.92 0.83 0.50 0.50 0.84 0.91 0.99 0.96 0.99 0.985
Earnings Smoothness
ROE Trend -0.80 -0.58 -1.19 -1.06 -0.91 -0.97 1.32 1.30 1.30 1.33 0.78 0.69 0.57 0.53 -0.17 -0.14 -0.11 -0.07 0.18 0.19 0.192
Gross Margin Trend
FCF Margin Trend
Sustainable Growth Rate
Internal Growth Rate
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.89 0.91 0.85 0.87 0.86 0.87 0.97 1.04 1.21 1.18 1.09 1.01 0.85 0.79 0.80 0.87 0.90 0.96 0.98 0.99 0.993
FCF/OCF 1.00 1.00 1.00 1.00 1.00 1.00 1.01 1.01 1.01 1.01 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.68 0.71 0.705
FCF/Net Income snapshot only 0.700
CapEx/Revenue
CapEx/Depreciation snapshot only 94.773
Accruals Ratio -0.07 -0.06 -0.12 -0.10 -0.10 -0.10 -0.01 0.01 0.07 0.06 0.02 0.00 -0.06 -0.09 -0.10 -0.06 -0.05 -0.02 -0.00 -0.00 -0.002
Sloan Accruals snapshot only 0.544
Cash Flow Adequacy snapshot only -3.390
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio
FCF Payout Ratio
Total Payout Ratio
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -20.7% -24.7% -1.3% -25.0% -39.4% -1.1% -55.6% -57.8% -22.7% -1.9% -0.0% -0.0% -0.1% -1.0% -12.9% -7.6% -23.4% -12.2% -6.0% -6.3% -6.34%
Total Shareholder Return -20.7% -24.7% -1.3% -25.0% -39.4% -1.1% -55.6% -57.8% -22.7% -1.9% -0.0% -0.0% -0.1% -1.0% -12.9% -7.6% -23.4% -12.2% -6.0% -6.3% -6.34%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.998
Interest Burden (EBT/EBIT) 1.03 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.04 1.03 1.01 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.96 0.964
EBIT Margin
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Equity Multiplier 1.31 1.31 1.93 1.93 1.93 1.93 1.30 1.30 1.30 1.30 1.12 1.12 1.12 1.12 1.10 1.10 1.10 1.10 1.08 1.08 1.076
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-1.74 $-1.62 $-1.57 $-1.07 $-0.52 $-0.47 $-0.30 $-0.29 $-0.28 $-0.27 $-0.29 $-0.34 $-0.38 $-0.44 $-0.45 $-0.40 $-0.36 $-0.32 $-0.29 $-0.31 $-0.31
Book Value/Share $1.36 $1.26 $0.79 $0.55 $0.29 $0.25 $1.10 $1.09 $1.09 $1.08 $0.83 $0.83 $0.82 $0.82 $0.94 $0.85 $0.76 $0.69 $1.26 $1.26 $1.18
Tangible Book/Share $1.36 $1.26 $0.79 $0.55 $0.29 $0.25 $1.10 $1.09 $1.09 $1.08 $0.83 $0.83 $0.82 $0.82 $0.94 $0.85 $0.76 $0.69 $1.26 $1.26 $1.26
Revenue/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
FCF/Share $-1.56 $-1.46 $-1.34 $-0.92 $-0.45 $-0.41 $-0.29 $-0.30 $-0.34 $-0.32 $-0.32 $-0.34 $-0.33 $-0.35 $-0.36 $-0.35 $-0.33 $-0.30 $-0.20 $-0.22 $-0.22
OCF/Share $-1.56 $-1.46 $-1.34 $-0.92 $-0.45 $-0.41 $-0.29 $-0.30 $-0.33 $-0.32 $-0.32 $-0.34 $-0.32 $-0.35 $-0.36 $-0.35 $-0.33 $-0.30 $-0.29 $-0.31 $-0.31
Cash/Share $2.24 $2.08 $1.70 $1.20 $0.62 $0.53 $1.23 $1.22 $1.22 $1.21 $0.83 $0.83 $0.82 $0.82 $1.02 $0.92 $0.83 $0.74 $1.29 $1.29 $1.18
EBITDA/Share $-1.69 $-1.56 $-1.51 $-1.03 $-0.50 $-0.45 $-0.29 $-0.28 $-0.27 $-0.26 $-0.29 $-0.33 $-0.38 $-0.44 $-0.45 $-0.40 $-0.36 $-0.32 $-0.29 $-0.32 $-0.32
Debt/Share $0.71 $0.66 $0.68 $0.47 $0.25 $0.21 $0.09 $0.09 $0.09 $0.09 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 $0.01
Net Debt/Share $-1.53 $-1.42 $-1.03 $-0.72 $-0.37 $-0.32 $-1.13 $-1.13 $-1.13 $-1.12 $-0.82 $-0.82 $-0.81 $-0.81 $-1.01 $-0.91 $-0.82 $-0.73 $-1.29 $-1.29 $-1.29
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 100.155
Altman Z-Prime snapshot only 177.853
Piotroski F-Score 1 1 1 1 2 1 4 3 3 3 1 1 2 2 2 2 2 3 4 4 4
Beneish M-Score
Ohlson O-Score snapshot only -1.143
ROIC (Greenblatt) snapshot only -25.93%
Net-Net WC snapshot only $1.25
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only A+
Credit Score 27.85 28.14 27.10 27.51 27.68 28.09 65.60 65.10 65.27 65.44 65.72 65.32 65.62 65.55 65.58 65.67 65.68 65.63 76.15 75.61 75.608
Credit Grade snapshot only 5
Credit Trend snapshot only 9.941
Implied Spread (bps) snapshot only 125.000
Industry Credit Rank snapshot only 76
Sector Credit Rank snapshot only 70

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms